8-K current report · filed Nov 10, 2026

Autolus Therapeutics plc (AUTL) 8-K Current Report: November 10, 2026

Item 2.02Item 7.01Item EX-99.1Item EX-99.2AUTL overview

Short answer

Autolus Therapeutics plc (AUTL) filed an 8-K current report with the SEC on November 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Q3 2026 financial results and corporate update announced for quarter ended September 30, 2026.

Autolus Therapeutics plc 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q3 2026 financial results and corporate update announced for quarter ended September 30, 2026
  • Press release furnished as Exhibit 99.1, containing the substantive financial and operational details

Item 7.01 · Regulation FD Disclosure

  • Updated corporate presentation accompanies the November 10, 2026 conference call on quarter ended September 30, 2026 results
  • Exhibit 99.2 likely contains management’s latest business, pipeline and financial messaging for investor review

Item EX-99.1 · Exhibit EX-99.1

  • Q3 AUCATZYL revenue $41.2M, up 95% year over year, validating accelerating demand across treatment centers
  • 2026 revenue outlook raised to at least the upper end of $150M, signaling stronger commercial execution
  • Gross margin reached 57%, supported by higher volumes and manufacturing efficiency, improving scalability
  • Net loss narrowed to $55.1M from $79.1M, while cash and securities totaled $248.4M at September 30
  • Cash runway extended into Q2 2028, including $100M from Perceptive’s credit facility, reducing near-term financing risk

Item EX-99.2 · Exhibit EX-99.2

  • Q3 2026 net product revenue $41.2M, up 95% versus Q3 2025; 9M revenue $113.1M, up 122%
  • 90 U.S. authorized treatment centers, exceeding the 2026 goal of more than 80
  • 2026 revenue expected at or above $150M, the upper end of prior guidance
  • Gross margin reached 57% in Q3 and 44% year-to-date, signaling improving commercial economics
  • Cash, equivalents and marketable securities totaled $248.4M, with funding expected into Q2 2028 including $100M from Perceptive’s credit facility

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Autolus Therapeutics plc 8-K filings

Get the next AUTL 8-K as it lands

Follow AUTL for push alerts, or ask the research agent what this filing means.